This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported by Sandoz Inc, Princeton, NJ, USA.
Reference
Wang W, et al. Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework. JCO Oncology Practice : OP2000994, 7 May 2021. Available from: URL: http://doi.org/10.1200/OP.20.00994
Rights and permissions
About this article
Cite this article
Switch to biosimilar G-CSFs for patients at risk chemotherapy-induced febrile neutropenia yields substantial cost savings. PharmacoEcon Outcomes News 879, 26 (2021). https://doi.org/10.1007/s40274-021-7749-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7749-1